Home
Anvisa

Anvisa Market Share Analysis for November 2025

Health > Health - Other

Domainanvisa.gov.br

Year Founded--

Employees1001 - 5000

Annual Revenue--

Anvisa

Anvisa (including company regionals)

anvisa.gov.br

See more website traffic and engagement information

Total visits to Anvisa's top domains

Understand Anvisa market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

anvisa.gov.br736.1K

See more with Sales Intelligence

Avg. visit duration in Anvisa's top domains

Analyze Anvisa engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

anvisa.gov.br00:04:15

See more with Sales Intelligence

Avg. pageviews on Anvisa's top domains

See how Anvisa keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

anvisa.gov.br5.38

See more with Sales Intelligence

Anvisa top competitors by domain

Top similar sites in November 2025, ranked by their affinity

Top technologies used by Anvisa

These are the website technologies, by industry, used by Anvisa top domains

Social (10)

Google+ Platform

Conversion & Analytics (3)

Google Analytics

Audio Video Media (2)

YouTube

Widget (2)

Google Maps

More Technologies

3

See all

News & Signals from Anvisa

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAnvisa launched NOTIVISA on Jan 1st '06.In 2006, Anvisa launched NOTIVISA, a nationwide system for reporting adverse events, which allowed the entire health system to learn from complications and product failures.

NewsAnvisa launched Resolution RDC 741/2022 on Aug 1st '22.In August 2022, ANVISA published Resolution RDC 741/2022 (link in Portuguese), which set the framework to consider other medical device market regulators’ authorizations.

NewsAnvisa launches “E-Participa” report.Last February, ANVISA published the “E-Participa” report, compiling contributions sent between October and November 2022 for the purposes of reviewing RDC 327/2019, which provides for Cannabis products for human medicinal use.